- More than two dozen state prosecutors send a letter to the FDA asking the agency to reconsider its approval of the new Zogenix (ZGNX +3%) painkiller Zohydro, saying the narcotic pill could add to the national epidemic of prescription drug abuse.
- The FDA approved Zohydro in October, making it the first single-ingredient hydrocodone drug ever cleared for U.S. patients; the pill uses an extended release formulation reportedly 5x-10x more potent than currently available hydrocodone combination pills such as Vicodin.
- ZGNX has said it is working on a version of the drug that is more difficult to abuse.
States ask FDA to reconsider approval of Zogenix painkiller
From other sites
at CNBC.com (Apr 10, 2014)
at CNBC.com (Mar 14, 2014)
Video at CNBC.com (Mar 11, 2014)
at CNBC.com (Mar 5, 2014)
at CNBC.com (Oct 28, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs